Management of Nausea and Vomiting After Starting Ozempic (Semaglutide)

Understanding Semaglutide-Related Gastrointestinal Effects

• Gastrointestinal side effects, particularly nausea and vomiting, are common with GLP-1 receptor agonists like semaglutide, occurring in 15-20% of patients, and are usually transient, improving over several weeks to months with continued use, according to the American College of Cardiology 1, 2

Assessment and Management Approach

Initial Assessment

• Rule out other potential causes of nausea/vomiting unrelated to medication, as recommended by the Journal of Clinical Oncology 3
• Check if the patient is taking the appropriate starting dose, typically the lowest available dose, as suggested by the American College of Cardiology 1

Management Strategies

Non-pharmacological Interventions (First-line)

• Recommend eating smaller portion meals, as advised by the American College of Cardiology 1
• Advise slow, gradual dose titration, ensuring the patient started with the lowest dose, as recommended by the American College of Cardiology 1
• Reassure the patient that symptoms are usually self-limited with longer-acting GLP-1 receptor agonists like semaglutide, according to the American College of Cardiology 1

Pharmacological Interventions (If needed for severe symptoms)

• Consider temporary antiemetic therapy for breakthrough nausea/vomiting that is severe or affecting quality of life, as suggested by the Journal of Clinical Oncology 3, 4

Special Considerations

• Use GLP-1 receptor agonists with caution in patients with history of clinically significant gastroparesis, as recommended by the American College of Cardiology 1

When to Consider Dose Adjustment or Discontinuation

• Consider dose adjustment or discontinuation if symptoms significantly impact quality of life or medication adherence, as suggested by Kidney International 2

Follow-up Recommendations

• If treatment is suspended due to intolerable side effects, reinitiation should begin at the lowest dose with gradual up-titration to minimize recurrent nausea and vomiting, as recommended by the American College of Cardiology 1
• Educate the patient that these side effects typically improve with continued use, according to Kidney International 2
• Reassure that experiencing these side effects does not indicate gastrointestinal pathology in most cases, as stated by the American College of Cardiology 1

Common Pitfalls to Avoid

• Discontinuing the medication too quickly without trying supportive measures first, as cautioned by the American College of Cardiology 1
• Failing to start with the lowest possible dose and titrating too rapidly, as warned by the American College of Cardiology 1
• Overlooking the potential for delayed absorption of other oral medications due to gastroparesis effects, as noted by Kidney International 2